LRRK2-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial

Journal:
Nature Medicine
Published:
Affiliations:
23
Authors:
36
Institutions Authors Share
Biogen, United States of America (USA)
17.000000
17.000000
0.47
Ionis Pharmaceuticals, United States of America (USA)
3.000000
0.08
Biogen Switzerland AG, Switzerland
2.000000
0.06
Montreal Neurological Institute and Hospital (MNI), McGill University, Canada
1.000000
0.03
Tel Aviv Sourasky Medical Center, Israel
1.000000
0.03
UCL, United Kingdom (UK)
1.000000
0.03
Selkirk Neurology, PLLC, United States of America (USA)
1.000000
0.03
Oregon Health and Science University (OHSU), United States of America (USA)
1.000000
0.03
Michigan Institute for Neurological Disorders, United States of America (USA)
1.000000
0.03
Northwestern University (NU), United States of America (USA)
1.000000
0.03
University of Tennessee Medical Center (UTMC), United States of America (USA)
1.000000
0.03
University of Pennsylvania (Penn), United States of America (USA)
1.000000
0.03
University Hospital General de Catalunya - Quirónsalud Group, Spain
1.000000
0.03
University of Bergen (UIB), Norway
0.666667
0.02
Takeda Pharmaceuticals U.S.A., Inc., United States of America (USA)
0.500000
0.01
August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Spain
0.500000
0.01
Biomedical Research Networking Centers (CIBER), Spain
0.500000
0.01
DaCapo Brainscience, United States of America (USA)
0.500000
0.01
Institute of Biomedicine of Seville (IBiS), Spain
0.333333
0.01
Biomedical Research Networking Center on Neurodegenerative Diseases (CIBERNED), Spain
0.333333
0.01
University of Seville (US), Spain
0.333333
0.01
Haukeland University Hospital, Norway
0.333333
0.01